Mythili Koneru
CIK 1776659 · View on SEC EDGAR ↗
First SEC filing: May 15, 2019 · Latest: May 15, 2019
On this page
- Insider at Companies where this person is a reporting insider.
- Insider transactions Every share this person bought or sold, from Form 4 filings.
- Derivatives Options and other derivative holdings reported by this person.
- Initial holdings The stakes this person held when they first started reporting.
- Compensation Executive pay disclosed in company proxy statements.
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
No open-market trades on record; showing all filings.
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| Feb. 27, 2023 | MRKR | A | 51,918 | — | — | 51,918 Direct | — | Acquired | (price as of 2026-08-21) |
| Feb. 17, 2022 | MRKR | A | 160,000 | — | — | 160,000 Direct | — | Acquired | (price as of 2026-08-21) |
| Feb. 10, 2021 | MRKR | A | 140,000 | — | — | 140,000 Direct | — | Acquired | (price as of 2026-08-21) |
| March 10, 2020 | MRKR | A | 116,100 | — | — | 116,100 Direct | — | Acquired | (price as of 2026-08-21) |
| March 10, 2020 | MRKR | A | 23,900 | — | — | 23,900 Direct | — | Acquired | (price as of 2026-08-21) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| Feb. 27, 2023 | MRKR | Employee Stock Option (right to buy) | Common Stock (51,918) | $2.14 | Feb. 27, 2033 | 51,918 | Acquired |
| Feb. 17, 2022 | MRKR | Employee Stock Option (right to buy) | Common Stock (160,000) | $0.46 | Feb. 17, 2032 | 160,000 | Acquired |
| Feb. 10, 2021 | MRKR | Employee Stock Option (right to buy) | Common Stock (140,000) | $3.29 | Feb. 10, 2031 | 140,000 | Acquired |
| March 10, 2020 | MRKR | Employee Stock Option (Right to Buy) | Common Stock (116,100) | $2.12 | March 10, 2030 | 116,100 | Acquired |
| March 10, 2020 | MRKR | Employee Stock Option (Right to Buy) | Common Stock (23,900) | $2.12 | March 10, 2030 | 23,900 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 2 holdings
Securities held when first becoming an insider, per SEC Form 3.
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
MRKR
Chief Medical Officer| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2019 | $313,542 | $50,000 | — | $1,438,656 | $41,565 | — | — | $1,843,763 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.